Scientists at the Salk Institute in the United States have developed a method called Superb-seq that can detect both intended and unintended DNA changes caused by CRISPR gene editing and determine how they affect the functioning of individual cells. The new method could help improve the safety of gene therapies.
The discovery of CRISPR/Cas9 technology in 2012 opened up new possibilities in genetics. It enabled scientists to cut, remove or replace specific sections of DNA to study how genes work and treat inherited diseases. However, the technology has a major drawback: it can sometimes cause changes in DNA regions that scientists did not intend to target.
Existing methods can identify where such unintended changes occur, but they cannot determine exactly which cells are affected or how the changes influence their function. Superb-seq addresses this gap by combining Cas9 gene editing, a short DNA sequence that records genetic changes, and RNA analysis of individual cells.
The scientists tested the method on 34,000 cells from three different cell lines. In a group of 10,000 human leukemia cells grown in the laboratory, it identified 43 sites of genetic changes, 36 of which were unintended. It also detected 5,761 cells carrying these changes.
The researchers also found that Superb-seq can detect changes in gene activity that are not visible using currently available methods. It provides a more comprehensive picture than the earlier Perturb-seq method, which showed gene activity and the guide RNA used but did not reveal the actual outcomes of genetic changes.
The study's authors believe the new method could be used in basic scientific research, drug development, personalized medicine and the improvement of machine learning models. Since human genomes differ, the same gene-editing procedure can produce different unintended changes in different people. Superb-seq could help identify these differences and select safer treatment options.
The study was published on November 16 in the scientific journal Nature Methods. The researchers have also filed a patent application for the new method.
Success in gene editing is not simply a matter of changing the DNA segment a scientist wants to target. It is equally important to understand what happens inside the cell after the intervention, since unintended changes can go unnoticed if researchers can identify only where they occur but not their consequences.
This is particularly important as CRISPR evolves from a laboratory tool into a means of treating diseases. Assessing the safety of gene therapy requires understanding not only the effects of the intended change but also what other alterations have occurred and whether they affect normal cell function. Superb-seq's main advantage is its ability to reveal this connection.
Nevertheless, the reported findings do not mean that the method has solved all the safety challenges associated with gene therapy. So far, it has been tested on three cell lines, and further applications will show how effective it is under different genetic conditions.

